Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1964 1
1966 3
1969 1
1973 1
1974 2
1975 1
1976 2
1977 2
1978 1
1979 1
1980 4
1981 2
1982 3
1983 5
1984 5
1985 1
1986 4
1987 5
1988 5
1989 8
1990 5
1991 6
1992 2
1993 6
1994 4
1995 3
1996 11
1997 6
1998 3
1999 6
2000 5
2001 6
2002 6
2003 8
2004 1
2005 7
2006 10
2007 11
2008 19
2009 15
2010 12
2011 20
2012 25
2013 33
2014 57
2015 75
2016 95
2017 76
2018 82
2019 53
2020 44
2021 54
2022 38
2023 40
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

822 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU; C4591001 Clinical Trial Group. Thomas SJ, et al. N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15. N Engl J Med. 2021. PMID: 34525277 Free PMC article. Clinical Trial.
Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. ...
Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B. …
The Oswestry-Bristol Classification.
Sharma N, Brown A, Bouras T, Kuiper JH, Eldridge J, Barnett A. Sharma N, et al. Bone Joint J. 2020 Jan;102-B(1):102-107. doi: 10.1302/0301-620X.102B1.BJJ-2019-0366.R3. Bone Joint J. 2020. PMID: 31888364
It can be applied in clinical practice to simplify and standardize surgical decision-making in patients with recurrent patella instability. Cite this article: Bone Joint J 2020;102-B(1):102-107....
It can be applied in clinical practice to simplify and standardize surgical decision-making in patients with recurrent patella instability. …
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simões EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Rämet M, Munjal I, Perez JL, Frenck RW Jr, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Türeci Ö, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Walter EB, et al. N Engl J Med. 2022 Jan 6;386(1):35-46. doi: 10.1056/NEJMoa2116298. Epub 2021 Nov 9. N Engl J Med. 2022. PMID: 34752019 Free PMC article.
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
Gray GE, Bekker LG, Laher F, Malahleha M, Allen M, Moodie Z, Grunenberg N, Huang Y, Grove D, Prigmore B, Kee JJ, Benkeser D, Hural J, Innes C, Lazarus E, Meintjes G, Naicker N, Kalonji D, Nchabeleng M, Sebe M, Singh N, Kotze P, Kassim S, Dubula T, Naicker V, Brumskine W, Ncayiya CN, Ward AM, Garrett N, Kistnasami G, Gaffoor Z, Selepe P, Makhoba PB, Mathebula MP, Mda P, Adonis T, Mapetla KS, Modibedi B, Philip T, Kobane G, Bentley C, Ramirez S, Takuva S, Jones M, Sikhosana M, Atujuna M, Andrasik M, Hejazi NS, Puren A, Wiesner L, Phogat S, Diaz Granados C, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, McElrath MJ, Gilbert PB, Janes H, Corey L; HVTN 702 Study Team. Gray GE, et al. N Engl J Med. 2021 Mar 25;384(12):1089-1100. doi: 10.1056/NEJMoa2031499. N Engl J Med. 2021. PMID: 33761206 Free PMC article. Clinical Trial.
A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. ...
A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. ...
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.
Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP; iDCL Trial Research Group. Breton MD, et al. N Engl J Med. 2020 Aug 27;383(9):836-845. doi: 10.1056/NEJMoa2004736. N Engl J Med. 2020. PMID: 32846062 Free PMC article. Clinical Trial.
Racial Inequality in Receipt of Medications for Opioid Use Disorder.
Barnett ML, Meara E, Lewinson T, Hardy B, Chyn D, Onsando M, Huskamp HA, Mehrotra A, Morden NE. Barnett ML, et al. N Engl J Med. 2023 May 11;388(19):1779-1789. doi: 10.1056/NEJMsa2212412. N Engl J Med. 2023. PMID: 37163624 Free PMC article.
Response to letter.
Chen LH, Barnett ED, Wilson ME, MacLeod W, Yanni EA, Ooi W, Karchmer AW, Kogelman L, Marano N, Hamer DH. Chen LH, et al. J Travel Med. 2013 May-Jun;20(3):210. doi: 10.1111/jtm.12028_2. J Travel Med. 2013. PMID: 23577870 Free article. No abstract available.
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Graf J, et al. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):e919. doi: 10.1212/NXI.0000000000000919. Print 2021 Jan. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 33411674 Free PMC article. Review.
Currently, ocrelizumab and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This part of the review focuses on monoclonal antibody B cell-depleting strategies in NMOSD and the emerging related myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G …
Currently, ocrelizumab and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This part of the review focuses on monoclo …
Ensemble Reweighting Using Cryo-EM Particle Images.
Tang WS, Silva-Sánchez D, Giraldo-Barreto J, Carpenter B, Hanson SM, Barnett AH, Thiede EH, Cossio P. Tang WS, et al. J Phys Chem B. 2023 Jun 22;127(24):5410-5421. doi: 10.1021/acs.jpcb.3c01087. Epub 2023 Jun 9. J Phys Chem B. 2023. PMID: 37293763
822 results